D-3⏰Time's almost up! After this Friday, the submission for Abstracts & Cases closes permanently, and this very last opportunity to present at #TCTAP2026 will not return. Hurry and submit your paper today and stand in the spotlight in Seoul next April! 🔗 https://t.co/R7mqroK67q

@anish_koka Just because it’s free doesn’t mean it’s accessible. We need to stop trying to condense these difficult issues into soundbites and or clickbait. That’s why we continue to go in circles. Lack of access is a very multifaceted problem that requires us to shed dogmas to address

CELEBRATE trial: Zalunfiban, a novel platelet GPIIb/IIIa inhibitor, given subcutaneously at first medical contact significantly improved coronary patency and 30-day CV outcomes vs. placebo in STEMI patients, with no increase in severe bleeding. #AHA25 View the slides here:

NEJM rarely publishes meta-analysis (NEJM Evidence does), but this is a good one! @NEJM https://t.co/FhTnIcy7YV

@SMPatelMD @crfheart @ASE360 @hahn_rt @DeeDeeWangMD @gb_mackensen @iamritu @purviparwani @dr_benoy_n_shah @ChamsiPash @ibrahem_albakry @DrAlbinmousa @HiteshiKc @adityadoc1 @sbrugaletta @drptca A humbled FASE too..really worth tapping into the lectures once available..nothing is as simple as we think In fact heard other revelations “there are limitations to the Gorlin formula acknowledged by Gorlin” “MG isn’t the ultimate test for valve function & invasive

My favorite quote of working in cath lab comes from someone who is not an interventional cardiologist , I just got punched in the face (again) yesterday! Will share soon as I recover!

@Hragy The problem is we never get used to the punches and they seem to hurt harder every time. Take some time to breathe and heal. Another battle is around the corner. You’ll bounce back, wiser, if that’s even possible.

Pressure to publish jumps. And researchers have no time to do science. (New survey from Elsevier) Survey of 3200 researchers: 1. Only 45% of scientists have sufficient time for actual research. 2. For 68%, the pressure to publish today is greater than 2-3 years ago. 3. 29% of

If you can get your LDL < 55 naturally. Good for you. If you can’t, and you have ASCVD or DM - start with a statin. Maximize intensity to balance tolerance. If you’ve had an MI, start a statin anyhow. This is what a good doctor would recommend.

@benhibbertMDPhD @cardiacpolymath @drjohnm Agreed. This is why trials in this space need to be powered to assess both efficacy and safety-- not the sum of both. If not, we will have limited ability to properly individualize treatment to different patient risk profiles.

Presented at #AHA25: In patients with atrial fibrillation after successful ablation, rivaroxaban therapy did not lead to a significantly lower incidence of a composite of stroke, systemic embolism, or new covert embolic stroke than aspirin therapy. Full OCEAN trial results:

Poor @VietHeartPA gets forced to do these crazy things with me. I wrote this silly rap about #SharedDecisionMaking & made him do this with me. All blame resides on me. But let’s do more SDM with our patients Read more at: 📎 https://t.co/wD2KCU1au2 📎 https://t.co/hKQRs7bxNb

@RodrigoBagur @mmamas1973 I don’t think that the observational study at the top of this thread contributes any meaningful information to the treatment decision because of its obvious flaws. 1/x

Unless there are fundamental comorbidities that preclude surgery such young patients shouldn't be having TAVIs. Sure we can do such procedures with relatives ease- but it doesn't mean it's right for the patient. They have to deal with the consequences long after you or I have

New in #JACCINT: “New-Onset Conductance Disturbances After Transcatheter Tricuspid Valve Replacement.” This study reports a 44% incidence of conduction disturbances post-TTVR, linked to hyperdynamic RV function and device–membranous septum. https://t.co/YAolyn5VR8

Amazing visualization of the heart’s valves in action 📸: smartdoctor

The prisoner’s dilemma in A.I. healthcare— when rational A.I. use leads to harmful outcomes Our new piece @TheLancet w/@pranavrajpurkar and Michael Moritz https://t.co/wdq7AvZJ6d

Great to do opening live case at #ISICAM with medina 1.1.1 lms disease and diffuse lad disease. Oct and physiology guided provisional hybrid approach with prox lad stent into lms, then cutting balloon guided seloution dcb in mid lad with @Iryuza @aninkasaboe @uziyahya46

A privilege to join leadership at the Royal Commission - Yanbu @RCJY_Intl to discuss multilevel collaborations: 🫀Generating national evidence @SaudiMedJ 🫀Presenting national projects @TCT_ME_

📢𝑫𝑬𝑨𝑫𝑳𝑰𝑵𝑬 𝑬𝑿𝑻𝑬𝑵𝑫𝑬𝑫! (+ 1 Week) The submission deadline for #TCTAP2026 Abstracts & Cases has been extended by one week! No further extensions will be granted, so make sure to submit your work by next Friday, November 14. 🔗Go Submit: https://t.co/R7mqroKDWY